

JPW)

CERTIFICATE OF MAILING

Thereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on October 2, 2004.

Aby | F. Viewe

PATENT Docket No. 3352.2.1.4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Yao Xiong Hu)
Serial No.:	10/827,083)))
Filed:	April 19, 2004) At Ollit.) 1645
For:	IMMUNOLOGICAL METHODOLOGY FOR DISCERNING HUMAN PAPILLOMAVIRUS CONTEMPLATING PEPTIDES FROM THE E7 EARLY CODING REGION OF HPV 16	,)))

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

This Information Disclosure Statement discloses information which has come to the attention of Applicant and/or his attorneys and is being submitted so as to comply with the duty of disclosure set forth in 37 C.F.R. § 1.56. In accordance with 37 C.F.R. § 1.97(b), this Statement is being filed within three (3) months of the filing date of the above-identified application or before the mailing date of a first Action on the merits.

Neither Applicant nor his attorneys make any representation that any information disclosed herein may be "prior art" within the meaning of that term under 35 U.S.C. §§ 102 or 103. Moreover, pursuant to 37 C.F.R. § 1.97, the filing of this Information Disclosure Statement shall not be

construed as a representation that a search has been made or as an admission that the information

cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.98, this Information Disclosure Statement includes and is

accompanied by:

1. A completed copy of Form PTO-1449 listing the patents, publications and other

information being submitted for consideration; and

2. A legible copy of each patent, publication and other item of information in written

form listed on the enclosed Form PTO-1449, excluding copies of references falling

under the prior submission or citation exception of 37 C.F.R. § 1.98(d).

Various patents, publications, and other items of information listed on the accompanying

Form PTO-1449 were previously cited by and/or submitted to the U.S. Patent and Trademark Office

in Applicant's prior application (Application Serial No. 09/828,645 filed April 5, 2001 for

"IMMUNOLOGICAL METHODOLOGY FOR DISCERNING HUMAN PAPILLOMAVIRUS",

now issued as U.S. Patent No. 6,743,593), which is being relied upon for an earlier filing date under

35 U.S.C. § 120. In accordance with 37 C.F.R.§ 1.98(d), copies of these patents, publications, and

other items of information are not being submitted with this Statement.

DATED this 20th day of October, 2004.

Respectfully submitted,

Gary D.E. Pierce

Attorney for Applicant

Reg. No.: 38,019

Date: October 20, 2004

PATE PIERCE & BAIRD

550 Park Side Tower

215 South State Street Salt Lake City, Utah 84111

Telephone: (801) 530-0330 Facsimile: (801) 530-5955



LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

SERIAL NO. 10/827,083	ATTORNEY DOCKET	
	3352.2.1.4	
FILING DATE April 19, 2004	GROUP ART UNIT 1645	
APPLICANT:		
Yao	Xiong Hu	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	PUBLICATION DATE (MM-DD-YYYY)	NAME OF PATENTEE OR APPLICANT	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR FIGURES APPEAR
	A1	4,777,239	11/11/1988	Schoolnik et al.	All
	A2	5,629,146	05/13/1997	Dillner et al.	All
	A3	5,629,161	05/13/1997	Muller et al.	All
	A4	5,753,233	05/19/1998	Bleul et al.	All
	A5	5,932,412	08/03/1999	Dillner et al.	All
	A6	6,096,869	08/01/1999	Stanley et al.	All
	A7	6,183,746	02/06/2001	Urban et al.	All

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	PUBLICATION DATE (MM-DD-YYYY)	NAME OF PATENTEE OR APPLICANT	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR FIGURES APPEAR	Т
	A8	WO 87/01375	03/12/1987	Breitburd et al.	All	
	A9	EP 0344940	12/12/1989	Dillner et al.	All	
	A10	EP 0 594 613	11/28/1991	Dillner et al.	All	
	A11	WO 99/10744	03/04/1999	Medigene	All	

NON-PATENT DOCUMENTS

EXAMINER INITIAL		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	A12	HAYWARD et al., Who gets screened for cervical and breast cancer?, Archives of Internal medicine, 148:1117-81, 1988.
	A13	HU YX, Introduction and prospect of application of biogenetic engineering, Guangzhou Medical Journal, 2:8-10, 1990

EXAMINER	DATE CONSIDERED

A14	KOCHEL et al., Antibodies to human papillomavirus type-16 in human sera as revealed by the use of prokaryotically expressed viral gene products, Virology, 182:644-54, 1991
A15	HARLAN et al., Cervical cancer screening: who is not screened and why?, American Journal of Public Health, 81:885-91, 1991
A16	SCHIFFMAN MH, Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia, Journal of the National Cancer Institute, 84:394-8, 1992
A17	LORINCZ et al., Human papillomavirus infection of the cervix: relative risk associations of 16 common anogenital types, Obstetrics and Gynecology, 79:328-37, 1992
A18	JOCHMUS et al., Detection of antibodies to the E4 or E7 proteins of human papillomaviruses (HPV) in human sera by western blot analysis: type specific reaction of anti-HPV 16 antibodies, Molecular and Cellular Problems, 6:319-25, 1992
A19	SLAWSON et al., Follow up papanicolau smear for cervical atypia: Are we missing significant disease?, Journal of Family practice, 36(3):289-93, 1993
A20	PARK et al., Human papillomavirus type 16 E6, E7, and L1 and type 18 E7 proteins produced by recombinant baculoviruses, Journal of Virological Methods, 45:303-318, 307, 1993
A21	HAMSIKOVA et al., Presence of antibodies to seven human papillomavirus type 16 derived peptides in cervical cancer patients and health controls, Journal of Infectious Disease, 170:1424-31, 1994
A22	HUTCHINSON et al., Homogeneous sampling accounts for the increased diagnostic accuracy using the ThinPrep Processor, American Journal of Clinical Pathology, 101:215-33, 1994
A23	FU et al., Diagnosis between condyloma acuminatum and pseudocondyloma in lower female genital tract as determined by a PCR-based method, Chinese Journal of Obstetrics and Gynecology, 29:168-88, 1994
A24	FU et al., Human papillomavirus and papillomatosis lesion of female lower genital tract, Infectious Disease Obstetrics and Gynecology, 10:235-41, 1994
A25	MULLER et al., Antibodies to the E4, E6 and E7 proteins of human papillomavirus (HPV) type 16 in patients with HPV-associated disease and in the normal population, Journal of Investigative Dermatology, 104:138-41, 1995
A26	GREGOIRE et al., Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma, Journal of the National Cancer Institute, 87(22):1705-9, 1995
A27	CHEE et al., Immunologic diagnosis and monitoring of cervical cancers using in vitro translated HPV proteins, Gynecology Oncology, 57:226-231, 1995
A28	COX et al., Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance, American Journal of Obstetrics and Gynecology, 172:946-64, 1995
A29	FERENCY et al., Diagnostic performance of hybrid capture human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytologic study, American Journal of Obstetrics and Gynecology, 1775:651-6, 1996
A30	DONNELLY et al., Protection against papillomavirus with a polynucleotide vaccine, Journal of Infectious Disease, 713:314-20, 1996
	A15 A16 A17 A18 A19 A20 A21 A22 A23 A24 A25 A26 A27 A28

EXAMINER	DATE CONSIDERED

15		
O'Claber Co	A31	BORYSLEWICZ et al., A recombinant vaccinia virus encoding human papillomavirus types 16 and 18 E6 and E7 proteins as immunotherapy for cervical cancer, Lancet, 347:1523-7, 1996
	A32	BIRDSONG C.G., Automated rescreening of Pap smears: what are the implications?, Diagnostic Cytopathology, 13:283-8, 1996
	A33	SOINI et al., Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma, Thorax, 51:887-93, 1996
	A34	ANONYMOUS, Cervical cancer, NIH Consensus Statement Apr 1-3; 14(1):1-38, 1996
	A35	KONYA et al., Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein, Journal of General Virology, 78:2615-20, 1997
	A36	VERDON ME, Issues in the management of human papillomavirus genital disease, American Family Physician, 55:1813-16, 1997
	A37	BRYAN et al., Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle, Journal of Med Virology, 53:185-8, 1997
	A38	SUGASE et al., Distinct manifestations of human papillomaviruses in the vagina, International Journal of Cancer, 72: 412-5, 1997
-	A39	CLAVEL et al., DNA-EIA to detect high and low risk HPV genotypes in cervical lesions with E6/E7 primer mediated multiplex PCR, Journal of Clinical Pathology, 51(1):38-43, 1998
	A40	LOWY et al., Papillomaviruses: prophylactic vaccine prospects, Biochimistre et Biophysica Acta, 1423(1):M1-8, 1998
	A41	ARENDS et al., Aetiology, pathogenesis, and pathology of cervical neoplasia, Journal of Clinical Pathology, 51:96-103, 1998
	A42	MESCHEDE et al., Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer, Journal of Clinical Microbiology, 36(2):475-80, 1998
	A43	RICE et al., High risk genital papillomavirus infections are spread vertically, Review of Medical Virology, 9:15-21, 1999
	A44	WALBOOMERS et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, Journal of Pathology, 189:12-19, 1999
	A45	SUN et al., Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma, Cancer Epidemiology Biomarkers & Prevention, 8(10):935-40, 1999
	A46	NOBBENHUIS et al., Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study, Lancet, 354:20-5; 1999
	A47	SILINS et al, Serological evidence for protection by human papillomarvirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis, Journal of General Virology, 80: 2931-6, 1999
	A48	HAGENSEE et al., Seroprevalence of human papillomavirus type 16 in pregnant women, Obstetrics and Gynecology, 94:653-8, 1999

EXAMINER	DATE CONSIDERED
]	

A49	CUZICK et al., A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions, British Journal of Cancer, 83(5):561-5, 2000
A50	PIROG et al., Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma, American Journal of Pathology, 157:1055-62, 2000
A51	FRISCH et al., Human papillomavirus-associated carcinomas in Hawaii and the mainland U.S., Cancer, 88(6):1464-9, 2000
A52	MELLIN et al., Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival, International Journal of Cancer (Pred. Oncol.), 89:300-4, 2000
A53	ZUMBACH et al., Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell carcinoma, International Journal of Cancer, 85:815-8, 2000
A54	WRIGHT et al., HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, Journal of the American Medical Association, 283:81-6, 2000
A55	DREAU et al., Human papilloma virus in melanoma biopsy specimens and its relation to melanoma progression, Annals of Surgery, 231(5):664-71, 2000
A56	PETTER et al., Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women, Journal of General Virology, 81:701-8, 2000

EXAMINER	DATE CONSIDERED